DECIPHERING THE ROLE OF CDK1 GENE IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSC) VIA THE MULTIFACETED BIOINFORMATICS APPROACH

Main Article Content

Hafeez Ullah
Zahid Rehman
Abid Hussain
Syeda Amber Hameed
Reema Bughio
Junaid Farooq
Zainab lanjar
Abdul Waheed khan
Ghulam Mustafa Solangi
Syed Meesam Raza
Habibullah Janyaro

Keywords

CDK1, HNSC, Biomarker, prognosis

Abstract

This study comprehensively analyzes the expression, promoter methylation, mutational, and survival status of CDK1 in Head and Neck Squamous Cell Carcinoma (HNSC) using various bioinformatics tools. Utilizing the UALCAN database, significant up-regulation of CDK1 expression is observed in HNSC tissues compared to normal controls, suggesting a potential role of CDK1 in HNSC proliferation. Concurrently, promoter methylation analysis reveals hyper-methylation of CDK1 in HNSC samples, indicating possible epigenetic dysregulation contributing to oncogenesis. Further investigation stratified by clinical parameters, including cancer stages, patient demographics, and age, unveils diverse relationships between CDK1 expression and these variables, underscoring its complex role in HNSC pathogenesis. Survival analysis utilizing the Km plotter tool demonstrates that higher CDK1 expression is associated with poorer overall survival rates among HNSC patients, indicating its potential as a prognostic biomarker. Additionally, mutational analysis using the cBioPortal platform reveals a low mutation rate in HNSC samples, with observed genetic alterations primarily consisting of amplifications and missense mutations. These findings collectively provide insights into the involvement of CDK1 in HNSC progression, highlighting its potential as a diagnostic and prognostic marker and emphasizing the need for further research to elucidate its exact mechanistic role in HNSC oncogenesis.

Abstract 136 | pdf Downloads 21

References

1. Krieghoff-Henning E, Folkerts J, Penzkofer A, Weg-Remers S. Cancer – an overview. Med Monatsschr Pharm. 2017 Feb;40(2):48-54.
2. Chandraprasad MS, Dey A, Swamy MK. 1 - Introduction to cancer and treatment approaches. In: Swamy MK, Pullaiah T, Chen Z-S, editors. Paclitaxel: Academic Press; 2022. p. 1-27.
3. Upadhyay A. Cancer: An unknown territory; rethinking before going ahead. Genes Dis. 2021 Sep;8(5):655-61.
4. Ahmad M, Khan M, Asif R, Sial N, Abid U, Shamim T, et al. Expression characteristics and significant diagnostic and prognostic values of ANLN in human cancers. International Journal of General Medicine. 2022:1957-72.
5. Khan M, Hameed Y. Discovery of novel six genes-based cervical cancer-associated biomarkers that are capable to break the heterogeneity barrier and applicable at the global level. Journal of Cancer Research and Therapeutics. 2023.
6. Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther. 2023 Jan 16;8(1):31.
7. Xu W, Li H, Hameed Y, Abdel-Maksoud MA, Almutairi SM, Mubarak A, et al. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma. Oncology Research. 2023;31(5):819.
8. Hameed A, Condò C, Tauseef I, Idrees M, Ghazanfar S, Farid A, et al. Isolation and characterization of a cholesterol-lowering bacteria from Bubalus bubalis raw milk. Fermentation. 2022;8(4):163.
9. Choi SY, Cheong HK, Lee MK, Kang JW, Lee YC, Oh IH, et al. Metabolic Diseases and Risk of Head and Neck Cancer: A Cohort Study Analyzing Nationwide Population-Based Data. Cancers (Basel). 2022 Jul 4;14(13).
10. Schicho A, Habicher W, Wendl C, Stroszczynski C, Strotzer Q, Dollinger M, et al. Clinical Value of Diffusion-Weighted Whole-Body Imaging with Background Body Signal Suppression (DWIBS) for Staging of Patients with Suspected Head and Neck Cancer. Tomography. 2022 Oct 9;8(5):2522-32.
11. Ribeiro IP, Esteves L, Caramelo F, Carreira IM, Melo JB. Integrated Multi-Omics Signature Predicts Survival in Head and Neck Cancer. Cells. 2022 Aug 16;11(16).
12. Usman M, Hameed Y. GNB1, a novel diagnostic and prognostic potential biomarker of head and neck and liver hepatocellular carcinoma. Journal of Cancer Research and Therapeutics. 2023.
13. Identification of Key Biomarkers for the Future Applications in Diagnostics and Targeted Therapy of Colorectal Cancer. Current Molecular Medicine. 2022.
14. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. Ca Cancer J Clin. 2021;71(1):7-33.
15. Mehraj U, Ganai RA, Macha MA, Hamid A, Zargar MA, Bhat AA, et al. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities. Cellular Oncology. 2021:1-21.
16. Enserink JM, Kolodner RD. An overview of Cdk1-controlled targets and processes. Cell division. 2010;5:1-41.
17. Morgan DO. The cell cycle: principles of control: New science press; 2007.
18. Panagopoulos A, Altmeyer M. The hammer and the dance of cell cycle control. Trends in biochemical sciences. 2021;46(4):301-14.
19. Bednarek K, Kiwerska K, Szaumkessel M, Bodnar M, Kostrzewska-Poczekaj M, Marszalek A, et al. Recurrent CDK1 overexpression in laryngeal squamous cell carcinoma. Tumor Biology. 2016;37:11115-26.
20. Sung W-W, Lin Y-M, Wu P-R, Yen H-H, Lai H-W, Su T-C, et al. High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients. BMC cancer. 2014;14:1-7.
21. Li M, He F, Zhang Z, Xiang Z, Hu D. CDK1 serves as a potential prognostic biomarker and target for lung cancer. Journal of International Medical Research. 2020;48(2):0300060519897508.
22. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. Journal of cancer research and clinical oncology. 2011;137:1409-18.
23. Usman M, Hameed Y, Ahmad M. Does epstein–barr virus participate in the development of breast cancer? A brief and critical review with molecular evidences. Biomedical and Biotechnology Research Journal (BBRJ). 2020;4(4):285-92.
24. Sofi S, Mehraj U, Qayoom H, Aisha S, Almilaibary A, Alkhanani M, et al. Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors. Med Oncol. 2022 Jun 20;39(9):133.
25. Hameed Y. Decoding the significant diagnostic and prognostic importance of maternal embryonic leucine zipper kinase in human cancers through deep integrative analyses. Journal of Cancer Research and Therapeutics. 2023;19(7):1852-64.
26. Karamat U, Ejaz S, Hameed Y. In silico-analysis of the multi-omics data identified the ataxia telangiectasia mutated gene as a potential biomarker of breast invasive carcinoma. Genetic Testing and Molecular Biomarkers. 2021;25(4):263-75.
27. Dong Y, Wu X, Xu C, Hameed Y, Abdel-Maksoud MA, Almanaa TN, et al. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures. Aging. 2024;16(3):2591-616.
28. Hu H, Umair M, Khan SA, Sani AI, Iqbal S, Khalid F, et al. CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology. American Journal of Translational Research. 2024;16(2):432.
29. Abdel-Maksoud MA, Ullah S, Nadeem A, Shaikh A, Zia MK, Zakri AM, et al. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis. American Journal of Translational Research. 2024;16(1):63.
30. Chen P, Yawar W, Farooqui AR, Ali S, Lathiya N, Ghous Z, et al. Transcriptomics data integration and analysis to uncover hallmark genes in hypertrophic cardiomyopathy. American Journal of Translational Research. 2024;16(2):637.
31. Abdel-Maksoud MA, Ullah S, Nadeem A, Khan QUA, Zia MK, Ali S, et al. PTPN3 in cancer: unveiling its immune-mediated impact on prognosis and dysregulated signaling pathways. American Journal of Translational Research. 2023;15(11):6464.
32. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020 Jul 2;48(W1):W509-w14.
33. Yeung ML, Tam TS, Tsang AC, Yao KM. Proteolytic cleavage of PDZD2 generates a secreted peptide containing two PDZ domains. EMBO Rep. 2003 Apr;4(4):412-8.
34. Jia B, Zhao X, Wang Y, Wang J, Wang Y, Yang Y. Prognostic roles of MAGE family members in breast cancer based on KM-Plotter Data. Oncol Lett. 2019 Oct;18(4):3501-16.
35. Hameed Y, Ahmad M, Ejaz S, Liang S. Identification of Key Biomarkers for the Future Applications in Diagnostics and Targeted Therapy of Colorectal Cancer. Curr Mol Med. 2022 Aug 19.
36. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012 May;2(5):401-4.
37. McCleary-Wheeler AL, Lomberk GA, Weiss FU, Schneider G, Fabbri M, Poshusta TL, et al. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 2013 Jan 28;328(2):212-21.
38. Yen CY, Huang HW, Shu CW, Hou MF, Yuan SS, Wang HR, et al. DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers. Cancer Lett. 2016 Apr 10;373(2):185-92.
39. Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters GJ, et al. Cyclin dependent kinase-1 (CDK-1) inhibition as a novel therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC). Cancers. 2021;13(17):4389.
40. Huang H-M, Huang X-Y, Wu S-P, Chen C-K, He X-H, Zhang Y-F. RETRACTED ARTICLE: Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1–AKT pathway. Cellular & molecular biology letters. 2022;27(1):28.
41. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nature reviews cancer. 2009;9(3):153-66.
42. Akar RO, Selvi S, Ulukaya E, Aztopal N. Key actors in cancer therapy: epigenetic modifiers. Turkish Journal of Biology. 2019;43(3):155-70.

Most read articles by the same author(s)

<< < 1 2